Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Neuroendocrine 1

Interventions

pembrolizumab 220 Carboplatin 219 Specimen Handling 197 Cisplatin 188 Magnetic Resonance Spectroscopy 166 Radiotherapy 152 Bevacizumab 143 Gemcitabine 135 Cyclophosphamide 134 Drug Therapy 118 Capecitabine 118 Paclitaxel 113 Oxaliplatin 110 Biopsy 105 venetoclax 102 Nivolumab 102 Rituximab 83 tislelizumab 81 durvalumab 81 toripalimab 77 Fluorouracil 73 Etoposide 73 Dexamethasone 69 sintilimab 67 Radiosurgery 67 Docetaxel 67 Pemetrexed 65 atezolizumab 64 Azacitidine 63 Injections 62

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Recruiting × DLL3 protein, human × Clear all

NCT06893783 2026-04-13

DeLLight

Asan Medical Center

Phase 2 Recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡